Aspire Biopharma Holdings reported revenue of $0.06M and net income of -$1.27M for the quarter ended Jun 2026. This income statement covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||
| Revenue | 0.00M | 0.00M | 0.03M | 0.06M | ||||||||||||||||||
| Cost of RevenueCost of Rev | 0.00M | 0.01M | 0.02M | 0.05M | ||||||||||||||||||
| Gross Profit | 884.00 | -0.00M | 0.01M | -0.03M | ||||||||||||||||||
| Operating items | ||||||||||||||||||||||
| Research & DevelopmentR&D | 0.09M | 0.01M | 0.02M | 0.04M | 0.26M | 0.35M | 0.43M | 0.10M | 0.33M | 1.22M | ||||||||||||
| Selling, General & AdministrativeSG&A | 0.02M | 755.00 | 0.11M | 0.30M | 0.26M | 0.31M | 0.32M | 0.29M | 0.32M | 0.40M | 0.13M | 0.09M | 0.19M | 0.53M | 15.07M | 0.40M | 0.51M | 1.66M | 1.02M | 0.97M | ||
| Restructuring CostsRestructuring | 0.09M | 0.40M | 0.23M | |||||||||||||||||||
| Other Operating ExpensesOther Opex | 0.01M | -0.09M | 0.01M | 0.10M | 0.22M | -0.34M | 0.21M | 0.09M | 0.30M | 0.23M | ||||||||||||
| Operating ExpensesOpex | 0.02M | 755.00 | 0.11M | 0.30M | 0.26M | 0.31M | 0.32M | 0.29M | 0.32M | 0.40M | 0.23M | 0.10M | 0.22M | 0.67M | 15.56M | 0.80M | 1.15M | 1.85M | 1.65M | 2.65M | ||
| Operating IncomeOp. Inc | -0.22M | -0.67M | -15.56M | -0.80M | -1.15M | -1.85M | -1.65M | -2.68M | ||||||||||||||
| EBIT | -0.22M | -0.67M | -15.56M | -0.80M | -1.15M | -1.85M | -1.65M | -2.68M | ||||||||||||||
| Non-operating items | ||||||||||||||||||||||
| Non Operating Interest Expenses | 0.18M | 0.29M | 0.53M | 1.48M | 6.23M | 1.60M | ||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.02M | 0.42M | 1.33M | 2.54M | 3.20M | 2.10M | 0.26M | 0.26M | 0.23M | 0.17M | ||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.09M | -0.36M | 0.78M | 3.47M | 0.25M | 1.35M | ||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 0.02M | 0.42M | 1.33M | 2.54M | 3.20M | 2.10M | 0.26M | 0.25M | 0.06M | -0.10M | -0.38M | -1.18M | -0.70M | -2.86M | -1.58M | 1.41M | ||||||
| Net income details | ||||||||||||||||||||||
| EBT | -0.22M | -0.67M | -15.94M | -1.98M | -2.63M | -8.08M | -3.22M | -1.27M | ||||||||||||||
| Tax ProvisionsTaxes | 0.00M | |||||||||||||||||||||
| Profit After TaxPAT | -0.02M | -755.00 | -0.09M | 0.12M | 1.08M | 2.23M | 2.87M | 1.81M | -0.07M | -0.15M | -0.23M | -0.10M | -0.22M | -0.77M | -15.94M | -1.98M | -1.85M | -4.71M | -3.22M | -1.27M | ||
| Income from Continuing OperationsIncome (Continuing) | -0.22M | -0.67M | -15.94M | -1.98M | -2.63M | -8.08M | -3.22M | -1.27M | ||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -0.22M | -0.67M | -15.94M | -1.98M | -2.63M | -8.08M | -3.22M | -1.27M | ||||||||||||||
| Income towards Parent CompanyParent Net Inc | -0.22M | -0.67M | -15.94M | -1.98M | -2.63M | -8.08M | -3.22M | -1.27M | ||||||||||||||
| Net Income towards Common StockholdersNet Income | -0.02M | -755.00 | -0.05M | 0.10M | 0.86M | 1.74M | 2.30M | 1.47M | -0.07M | -0.04M | -2.47M | -0.60M | -0.22M | -0.67M | -15.94M | -1.98M | -2.63M | -8.08M | -3.22M | -1.27M | ||
| Additional items | ||||||||||||||||||||||
| EPS (Basic) | -0.10 | 0.00 | -0.16 | 0.54 | 4.80 | 9.66 | 12.79 | 15.62 | -0.31 | -0.62 | -10.98 | -2.85 | -1.11 | -3.24 | -16.83 | -1.61 | -2.12 | -5.41 | -20.57 | -1.22 | ||
| EPS (Diluted) | -0.10 | 0.00 | -0.16 | 0.54 | 4.80 | 9.66 | 12.79 | 15.62 | -0.31 | -0.62 | -10.98 | -2.85 | -1.11 | -3.24 | -16.83 | -1.61 | -2.12 | -5.41 | -20.57 | -1.22 | ||
| Shares Outstanding | 0.16M | 0.16M | 0.29M | 0.18M | 0.18M | 0.18M | 0.18M | 0.09M | 0.22M | 0.07M | 0.22M | 0.21M | 0.19M | 0.21M | 0.95M | 1.23M | 1.24M | 1.49M | 0.16M | 1.04M | ||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.16M | 0.16M | 0.29M | 0.18M | 0.18M | 0.18M | 0.18M | 0.09M | 0.22M | 0.07M | 0.22M | 0.21M | 0.19M | 0.21M | 0.95M | 1.23M | 1.24M | 1.49M | 0.16M | 1.04M | ||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.34M | 0.34M | 1.08M | 1.08M | 1.08M | 1.08M | 1.08M | 0.50M | 0.32M | 0.25M | 0.22M | 0.25M | 0.18M | 0.21M | 0.95M | 1.24M | 1.24M | 1.49M | 0.16M | 1.04M | ||
| EBITDA | -0.22M | -0.67M | -15.56M | -0.80M | -1.15M | -1.85M | -1.65M | -2.68M | ||||||||||||||
| Interest ExpensesInt Expense | 0.18M | 0.29M | 0.53M | 1.48M | 6.23M | 1.60M | ||||||||||||||||
| Tax Rate | -0.47% |